New York, New York (PRWEB) August 21, 2013
GranuFlo lawsuits (http://www.granuflodialysislawsuits.com/) filed in the wake of last year’s recall for GranuFlo and NaturaLyte dialysis drugs continue to mount in the federal multidistrict litigation now underway in U.S. District Court, District of Massachusetts. Court documents indicate that the proceeding’s initial Status Conference will be convened on August 30, 2013 at 9:30 a.m. (In re Fresenius GranuFlo/Naturalyte Dialysate Litigation, MDL No. 2428)
“We continue to hear from alleged victims of the GranuFlo recall on a regular basis. We look forward to this conference, and additional progress in the litigation over the coming months,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm continues to offer free GranuFlo lawsuit evaluations to dialysis patients who may have been harmed by GranuFlo or NaturaLyte.
Last year, the U.S. Food & Drug Administration (FDA) announced a Class I GranuFlo recall, after Fresenius Medical Care issued an “Urgent Product Notification” in March 2012 to its customer clinics warning of possible heart risks associated with GranuFlo and NaturaLyte. Both drugs are administered during dialysis to reduce acid in the blood. According to the Urgent Product Notification, both had been associated with high levels of bicarbonate in the blood, which can lead to metabolic alkalosis, a significant risk factor for serious and potentially deadly cardiovascular problems, including low blood pressure, cardiac arrhythmia, cardiopulmonary arrest, and sudden cardiac death.
The New York Times reported last summer that the FDA had launched an investigation of Fresenius Medical Care’s handling of the GranuFlo recall, after learning that the company had issued a memo in November 2011 to its own clinics that warned of the heart risks associated with GranuFlo and NaturaLyte. However, clinics outside of the Fresenius network did not receive a similar warning until March 2012.*
Court documents indicate that more than 300 GranuFlo lawsuits are now pending in the District of Massachusetts. Plaintiffs allege that Fresenius Medical Care knew or should have known of the propensity of GranuFlo and NaturaLyte to cause injury. They also accuse the company of failing to provide adequate warnings regarding their use, and assert that Fresenius continued to aggressively market the products even after the company became aware of their dangers.
Dialysis patients who suffered heart attacks, sudden cardiac death, and other catastrophic heart side effects within 48 hours of a dialysis treatment with GranuFlo or NaturaLyte may be entitled to file a Granuflo lawsuit to obtain compensation for medical expenses, lost wages, pain and suffering, and more. Learn More about the GranuFlo recall by visiting Bernstein Liebhard LLP’s website. For additional information, please call 800-511-5092.
*nytimes.com/2012/06/15/health/fda-investigates-fresenius-for-failure-to-warn-of-risk.html; New York Times, June 14, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP